Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumanta Kumar Pal

Showing results (21-30 of 94) with videos related to

Pageof 10
Sort By:
Ebiomedicine|June 9, 2020
Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?Alexander Chehrazi-Raffle, Sumanta Kumar Pal
Targeted Oncology|July 16, 2010
Targeted therapies for renal cell carcinoma: understanding their impact on survivalSumanta Kumar Pal, Robert A Figlin
Clinical Interventions in Aging|December 15, 2010
Critical appraisal of cabazitaxel in the management of advanced prostate cancerSumanta Kumar Pal, Przemyslaw Twardowski, Oliver Sartor
CA: a Cancer Journal for Clinicians|February 23, 2010
Evaluating the older patient with cancer: understanding frailty and the geriatric assessmentSumanta Kumar Pal, Vani Katheria, Arti Hurria
Clinical Journal of Oncology Nursing|September 29, 2011
Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinomaLaura Bourdeanu, Przemyslaw Twardowski, Sumanta Kumar Pal
Maturitas|February 8, 2011
Management of non-small-cell lung cancer in the older adultAri VanderWalde, Sumanta Kumar Pal, Karen L Reckamp
Cancer Biology & Therapy|August 19, 2010
Deciphering the anticancer mechanisms of sunitinibSumanta Kumar Pal, Robert A Figlin, Hua Yu
Maturitas|September 8, 2009
Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathwaysSumanta Kumar Pal, Przemyslaw Twardowski, David Y Josephson
Breast Cancer Research and Treatment|December 17, 2010
Triple negative breast cancer: unmet medical needsSumanta Kumar Pal, Barrett H Childs, Mark Pegram
Current Opinion in Urology|August 1, 2020
Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be consideredLuis Meza, Alexander Chehrazi-Raffle, Sumanta Kumar Pal
Pageof 10

Showing results (21-30 of 94) with videos related to

Sort By:
Pageof 10
Ebiomedicine|June 9, 2020
Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?Alexander Chehrazi-Raffle, Sumanta Kumar Pal
Targeted Oncology|July 16, 2010
Targeted therapies for renal cell carcinoma: understanding their impact on survivalSumanta Kumar Pal, Robert A Figlin
Clinical Interventions in Aging|December 15, 2010
Critical appraisal of cabazitaxel in the management of advanced prostate cancerSumanta Kumar Pal, Przemyslaw Twardowski, Oliver Sartor
CA: a Cancer Journal for Clinicians|February 23, 2010
Evaluating the older patient with cancer: understanding frailty and the geriatric assessmentSumanta Kumar Pal, Vani Katheria, Arti Hurria
Clinical Journal of Oncology Nursing|September 29, 2011
Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinomaLaura Bourdeanu, Przemyslaw Twardowski, Sumanta Kumar Pal
Maturitas|February 8, 2011
Management of non-small-cell lung cancer in the older adultAri VanderWalde, Sumanta Kumar Pal, Karen L Reckamp
Cancer Biology & Therapy|August 19, 2010
Deciphering the anticancer mechanisms of sunitinibSumanta Kumar Pal, Robert A Figlin, Hua Yu
Maturitas|September 8, 2009
Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathwaysSumanta Kumar Pal, Przemyslaw Twardowski, David Y Josephson
Breast Cancer Research and Treatment|December 17, 2010
Triple negative breast cancer: unmet medical needsSumanta Kumar Pal, Barrett H Childs, Mark Pegram
Current Opinion in Urology|August 1, 2020
Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be consideredLuis Meza, Alexander Chehrazi-Raffle, Sumanta Kumar Pal
Pageof 10